ISG15 is an ubiquitin-like modifier that is associated with reduced survival rates in breast cancer patients. The mechanism by which ISG15 achieves this however remains elusive. We demonstrate that modification of Rab GDP-Dissociation Inhibitor Beta (GDI2) by ISG15 (ISGylation) alters endocytic recycling of the EGFR receptor (EGFR) in non-interferon stimulated cells using CRISPR-knock out models for ISGylation. By regulating EGFR trafficking, ISGylation enhances EGFR recycling and sustains Akt-signalling. We further show that Akt signalling positively correlates with levels of ISG15 and its E2-ligase in basal breast cancer cohorts, confirming the link between ISGylation and Akt signalling in human tumours. Persistent and enhanced Akt activation explains the more aggressive tumour behaviour observed in human breast cancers. We show that ISGylation can act as a driver of tumour progression rather than merely being a bystander.

Oncogene (2021) 40:6235–6247; https://doi.org/10.1038/s41388-021-02017-8

INTRODUCTION
Interferon-Induced 15 kDa protein (ISG15) was the first ubiquitin-like protein identified. However, its research was long restricted to the field of immune response where it was initially discovered. Recently, ISG15 has been associated with processes and pathologies distinct from the innate-immune response [1]. Tumour progression and aggresiveness of several cancer types, including endometrium, bladder, prostate, melanoma, colorectal, liver and breast cancer [2–9] has been correlated to ISG15 expression. However, the mechanism through which ISG15 regulates tumorigenesis remains elusive.

ISG15, like other ubiquitin-like proteins, can be covalently bound to lysine residues of target proteins [10] in a process known as ISGylation. This post-translational modification is similar to ubiquitination, as it requires a cascade involving three different ligases. The process can be reversed by the action of Ubiquitin-specific Peptidase 18 (USP18), a member of the deubiquitinase family which is the only ISG15-specific deubiquitinase enzyme that has been described so far [11].

Basal levels of ISG15 and ISGylation-related enzymes are generally low in cells. Protein expression can be substantially increased by a variety of stimuli, such as type I interferons [12], Lipopolysaccharide [13], growth factors [14] or viral infections [15]. In breast cancer cells, enhanced ISG15 expression is induced through exosome-mediated cGAS activation [9, 16] and from nuclear DNA release after DNA damage [17].

ISG15 functions either as unconjugated or as a covalently linked protein. When released into the extracellular matrix [18], it functions as an immunomodulatory agent for lymphocytes [19] or Natural Killer (NK) cells [20]. The role of secreted ISG15 during tumour development is contradictory. It has been described both as an antitumoural factor by increasing NK cell infiltration in xenografts [21] or tumourigenic by increasing the invasive potential of primary tumour cells [22]. As a conjugate, ISG15 is widely linked to immune functions. Initially it was considered an antiviral protein [23], although recent data in human models suggest that ISG15 functions as a negative effector of type I interferon signalling rather than directly regulating the immune system [24].

To comprehensively map the role of ISGylation numerous mass spectrometry-based studies have been carried out to identify substrates of ISG15 modification, the ISGylome [25–27]. These studies showed that ISG15 substrates are associated with multiple signalling pathways and are cell/tissue type dependent, thus suggesting that ISG15 might play beyond the interferon-associated response. However, only a few of these putative targets have been validated endogenously and even fewer have been functionally characterised by identifying the molecular role of the ISGylation. Despite this, it is apparent that the molecular function of ISGylation is varied. It has been shown to induce both protein stabilisation [28] and degradation [29, 30], as well as modulating protein–protein interactions [31, 32]. This plasticity makes ISG15 a dynamic post-translation modification that can regulate substrate function disparately.

In breast cancer models, ISG15 and/or ISGylation correlate with aggressive features such as, cell cycle progression, cell motility and
tumour growth in xenograft models [28, 29, 33], yet, we still do not know if ISG15 is just a bystander or indeed a driver. Progress in uncovering a functional link has been hampered by the lack of functional, mechanistic insight into how ISGylation regulates signalling networks. We decided to bridge this gap by applying unbiased, systems approaches to elucidate in detail how ISGylation contributes to cell signalling.

In this study, we aimed to identify the molecular mechanisms that explain why high ISG15/ISGylation correlates with poor patient prognosis in breast cancer.

RESULTS
ISGylation negatively correlates with disease-free survival
We used the Breastmark database [34] to analyse the correlation between prognosis, ISG15 levels and metastasis. As previously shown, elevated ISG15 mRNA levels correlated with lower disease-free survival (Fig. 1A). Surprisingly however, the correlation was only maintained in patients with identified lymph node metastasis (Fig. 1B, C).

ISG15 can function as a conjugated or free/secreeted protein, to narrow down which form is associated with this correlation, we determined if regulators of ISGylation showed an analogous correlation. We correlated disease free-survival with genes encoding the ISG15 E1 ligase UBE1L, (UBEA7) [35], and the main ISG15 E2 ligase UBC8/UbC8 (UBE2L6) [36]. As seen with ISG15, UBE2L6 mRNA expression levels negatively correlated with survival in patients with cancer that had spread to the lymph nodes whereas the correlation was lost in patients without lymph node metastasis (Fig. 1D). However, this correlation is not detected for UBE1L (Fig. S1A). Furthermore, the analysis of a second ISG15 E2 ligase, UBC8 (UBE2E1) [37] did not show a correlation with survival either (Fig. S1B). These data lead us to hypothesise that the correlation between ISG15 expression and survival was not because of a global increase in ISGylation, but was rather due to the specific, UBC8-dependent ISGylation of a subgroup of proteins.

Both, ISG15 and UBC8 are induced by interferon [36, 38], it would be therefore plausible that the correlation we observed was, in fact, due to enhanced interferon signalling. To determine this, we analysed if the correlation persisted with the upstream drivers, the type I interferons interferon alpha I and beta. Neither showed a correlation that was analogous to ISG15 and UBE2L6 (Fig. 1E, F). Other established interferon-induced genes such as IFITM1 and IRF3 (Fig. S1C, D), genes with an IFN-sensitive response element (ISRE) or Gamma interferon activation site (GAS), such as IF16 or IFIT2 (Fig. S1E, F) failed to show the same correlation. These data suggest that the correlation between ISG15 and UBE2L6 and survival are not only due to augmented interferon signalling.

ISGylation enhances cellular aggressiveness
The inverse correlation of both ISG15 and UBC8 expression with disease-free survival suggested that conjugated ISG15 enhances metastasis and tumour progression. To study this, we generated different cell line models with varying levels of ISGylation in MDA-MB-231-luc-D3H2LN. Using CRISPR/Cas9 and two specific gRNAs per gene, we either knocked-out ISG15 (criSG15), UBE2L6 (criUBC8), USP18 (criUSP18) or generated a control line with the same Cas9 expression plasmid but without targeting gRNA (WT). These four cell lines allowed us to test the molecular and cellular characteristics of cells devoid of ISG15 (criISG15), devoid of ISGylation (criUBC8), with enhanced levels of ISGylation (criUSP18). Western blotting (WB) confirmed the respective knockouts (Fig. 1G). To increase basal levels of ISG15, USP18, UBC8 and ISGylation we additionally incubated the cells with IFN1b 250pM (or vehicle), which facilitated the confirmation of protein depletion (Figs. 1G, 2A). The result confirmed that criSG15 expressed no free or conjugated ISG15, crUBC8 expressed unconjugated ISG15 and, as additional bands are detected in the criUSP18 in non-interferon stimulated cells, that USP18 knock-out enhanced basal ISGylation levels. Surprisingly, the interferon-induced ISGylation profile of WT and criUSP18 cells was indistinguishable suggesting that the system is saturated under the experimental conditions. Due to the intricate relationship between IFNS and ISG15 or USP18 levels [39], all further experiments were performed in the absence of interferon allowing us to deconvolute both pathways. The analysis of MDA-MB-231 secretome [40, 41] failed to detect type-I interferons as secreted factors, suggesting that ISGylation is at basal levels and the effects observed in the cell lines were not due to differences in autocrine interferon secretion.

Having generated these models, we assessed if cellular phenotypes associated with tumour aggressiveness were linked to ISGylation. We focused on proliferation, anchorage-independent growth and cell motility or invasion. We found a positive correlation between ISGylation and the proliferation rate (Fig. 2B), the ability to form colonies in soft agar (Fig. 2C), the cell-density of those colonies (Fig. S2A), and their total number (Fig. 2D). Using the different clones and in the presence or absence of EGF or serum, we assessed the migration potential of the individual cell lines in a wound-healing assay. In this assay only criUSP18 cells, showed a statistically significant increase in motility at different time points (Fig. 2E), suggesting that enhanced ISGylation may increases motility when compared to basal levels. USP18 knock-out also increased the ability of cells to invade into Matrigel. In addition, we observed a trend indicating that cells devoid of ISGylation, criSG15 and criUBC8, had a reduced ability to invade (Fig. S2B, C). Overall, these data suggest that in vitro ISGylation increases several markers of tumour aggressiveness in a basal breast cancer cell line.

ISGylation enables sustained Akt-signalling
ISG15 has been reported to regulate multiple signalling pathways, including Akt [42], ERK [27] or JAK/STAT [43]. To determine which are regulated by ISG15/UBC8-dependent-ISGylation, we employed a systematic approach. Using a Reverse Phase Protein Array (RPPA) we monitored how expression and phosphorylation of 58 signalling proteins were regulated at basal levels and upon EGF stimulation in the cell line panel (Fig. 3A). Despite not detecting significant changes in EGFR or EGFR phosphorylation levels between the clones, we identified downstream pathways that were regulated by ISGylation. As previously observed, cells lacking ISG15 had increased activated STAT1 [44]. In addition, we observed the increased expression of MAPKAPK2 [45]. Neither STAT1 nor MAPKAPK2 were altered in crUBC8 cells, it is therefore unlikely that UBC8-dependent ISGylation regulates these pathways. We further detected reduced ppERK levels in both criSG15 and crUBC8 at 10 min. when compared to WT and crUSP18, but the pathway most strikingly affected by ISGylation among all conditions was PI3K/Akt. pAktSer473 (pAkt) levels were positively correlated with ISGylation levels, with a maximal increase in motility lacking ISGylation, crISG15 and crUBC8, had a reduced ability to invade (Fig. S2B, C). Overall, these data suggest that in vitro ISGylation increases several markers of tumour aggressiveness in a basal breast cancer cell line.

Oncogene (2021) 40:6235 – 6247
several concentrations of insulin, a strong activator of the PI3K/Akt pathway. Like our observation with EGF, pAkt levels were suppressed in crISG15 compared to WT upon insulin stimulation, whereas receptor activation was unimpaired (Fig. S3D).

To determine if Akt suppression was due to altered feedback/network regulations, we performed time course experiments, stimulating the cells with EGF for 0, 2, 5, 10, 30 and 60 min. Our results (Fig. S3E, F) indicated that peak pAkt levels was...
unaffected. However, pAkt levels diverged depending on the ISGylation status, with pAkt suppressed at 10-, 30- and 60-minutes post-stimulation in clones lacking ISGylation. Conversely, Akt levels were augmented in crUSP18 cells at 10 min., suggesting that ISGylation influences the signalling sustenance rather than the acute activation.

ISGylation is required for efficient receptor recycling
ISGylation has been shown to regulate PTEN stability [46], but we were unable to detect any regulation of PTEN protein expression (Fig. S3G), ruling this mechanism out. It has been previously shown that EGFR recycling is a crucial determinant of Akt signalling duration [47]. To explore if the reduction in sustained Akt activation was due to changes in trafficking, we assayed basal EGFR recycling using a surface biotinylation assay [48]. Reducing ISGylation decreased EGFR plasma membrane recycling, whereas EGFR recycled at a faster rate when ISGylation was enhanced by USP18 knockout (Fig. 4A). Loss of ISGylation could ‘trap’ EGFR in specific cellular compartments, which would in turn reduce recycling. To explore this, we used immunofluorescence to assess EGFR localisation in WT and crISG15 cells at basal and after 10 min. EGF stimulation (Fig.S4A). The latter timepoint was selected as it coincides with the most robust differences of Akt activation observed in the knock-out clones. In basal conditions there is a slight reduction of EGFR localising to the plasma membrane in crISG15 cells (Fig. S4B). However, the reduction of plasma membrane EGFR did not limit EGFR phosphorylation (Fig. 3A–C), suggesting that the concentration of EGF is rate limiting. However,
after 10 min exposure, the differences in membrane-associated EGFR are more severe (Fig. S4B), which indicates that the defect in plasma membrane trafficking is exacerbated upon EGF stimulation. As expected, the EGFR localisation to early endosomes increased upon EGF stimulation, but this appeared to be independent of ISGylation (Fig. S4C). These data suggest that EGFR may be trapped in other compartments.

To assay ISGylation-dependent changes in EGFR subcellular distribution, WT and crISG15 cells were subjected to a fractionation protocol that generates a cytoplasmic fraction, containing the cytoplasm, cellular membrane and vesicles; a perinuclear fraction, containing the Golgi apparatus and endoplasmic reticulum, and a nuclear fraction. We detected that perinuclear EGFR was enhanced in cells lacking ISGylation (Fig. 4B).

The increased perinuclear localisation of EGFR in crISG15 cells could be due to increased shunting of EGFR towards the endoplasmic reticulum and/or the Golgi apparatus. To deconvolute de novo synthesised EGFR from EGFR expressed at the point of EGF stimulation, we pre-treated cells with cycloheximide, a protein translation inhibitor. Confocal imaging indicated that at 10 min. EGF stimulation in WT cells most of the internalised EGFR co-localised with EEA1-positive endosomal structures (Fig. S4A, C), however, a minority co-localised with GM130 (Fig. 4C), a Golgi apparatus marker. In crISG15 cells, we detected a statistically significant increase in the co-localisation between EGFR and GM130 (Fig. 4D). The increased localisation of EGFR in the Golgi in the absence of protein synthesis suggest that EGFR is trafficked and retained in the Golgi. Furthermore, we found that EEA1, EGFR and GM130 co-localised, indicative of increased retrograde transport (Fig. S4D). We also assessed if ISG15 affected EGFR shunting towards the lysosome by assaying co-localisation with CD63 and/or Lamp1 (Fig. S5A–C).
but could not detect significant differences between WT and criSG15 cells.

To test if retrograde transport could impact Akt, we treated the cells with Retro-2, an inhibitor of the endosome-to-Golgi transport [49]. Retro-2 partially rescued pAkt and inhibited EGFR Golgi localisation in criSG15 cells (Figs. 4E, S6), suggesting that reducing EGFR trafficking to the Golgi salvages Akt activation in criSG15 cells.

These data show that ISGylation reduces the proportion of the receptor trafficked to the Golgi and promotes the return of the receptor to the plasma membrane.

**ISGylation does not have a direct effect on protein stability**

To identify UBC8-dependent ISG15 substrate/s that control/s endosomal trafficking we devised two complimentary strategies. Firstly, ISG15 has been shown to regulate protein stability [28–30],
thus ISG15 could alter expression levels of proteins controlling endosomal trafficking. Analysis of protein expression of the different knockout lines showed that 96 proteins were differentially expressed in the clones, when compared to WT cells (Table S1), three of which have been associated with protein trafficking (SEC61B, SEHIL, VAC14). However, none of these three proteins had expression level changes that were consistent with the phenotype observed in crISG15, crUBC8 and crUSP18, making

Fig. 4 ISGylation promotes faster EGFR recycling. A Graph showing EGFR membrane recycling rate. Cells were surface labelled with NHS-SS-biotin, and surface receptors allowed to internalise for 30 min in serum free medium. Biotin remaining at the cell surface was removed, and internalised receptors allowed to recycle to the plasma membrane for the indicated time. Biotin label was removed from surface proteins at the cell membrane, cells were lysed and the fraction of recycled EGFR was determined at each timepoint. p-value < 0.05 (*), p value < 0.01 (**), p value < 0.005 (**). B Analysis by WB of EGFR localisation in WT and crISG15 cells stimulated with EGF for 10 min. Cells were fractionated into membrane and cytoplasm fraction (Cyt.), perinuclear region (Per) and nucleus (Nuc.). EGFR levels detected by WB in the different fraction and the presence of the respective markers of subcellular localisation, GAPDH (cytoplasm), GM130 (Golgi) and Histone 4 (H4; Nucleus). Whole cell lysates (WCL) were included as reference of relative protein expression. C Representative super-resolution confocal images, obtained at 100 ×, of WT and crISG15 cells pre-treated with cycloheximide for 15 min. and stimulated for 10 min. with EGF 10 ng/ml. Cells were fixed, permeabilised and incubated with antibodies as indicated. Images show EGFR in green, GM130 as Golgi marker in red, phalloidin in grey and DAPI in blue. At top right of each image, zoom of Golgi structure displayed. At bottom right of each image, visualisation of the co-localisation between EGFR and the Golgi marker GM130 of the images in yellow and DAPI, in blue as reference. 10 µm scale bars are displayed in the bottom-left corner. D Bar graph shows the average EGFR-GM130 co-localisation showed in C using Costes method, average ± SD; n = 8 field of view. p value < 0.05 (*) E Endosome to Golgi trafficking inhibition induces pAkt levels in crISG15 cells. WT and crISG15 cells treated for 10 min. with EGF. crISG15 cells were pre-treated with retro-2 for 15 min or not. Quantification of Akt activation, measured as pSer473-Akt/Akt signal, normalised to WT.

Fig. 5 GDI2 is ISGylated and can regulate pAkt levels. A Label-free quantification (LFQ) values for GDI2 obtained from ISG15 pull-downs of the indicated clones, protein identification and quantification were performed using MaxQuant. B Analysis of GDI2 ISGylation using crUBC8 and WT cells transfected with empty vector, Step-tactin-ISG15, MYC-DDK-GDI2 or both, and subjected to a Step-tactin pulldown. WB show the pulldown and a 5% of the total lysates (Input). Arrow indicates ISGylated GDI2. C WB of WT and crISG15 cells transfected with MYC-DDK-GDI2, after 48 h cells were lysed and subjected to an anti-Flag pull-down. Blots show the pulldowns and a 5% of the total lysates (Input). D Analysis of putative GDI2 ISGylation sites. WT cells were transfected with Strep-tactin ISG15, MYC-DDK-GDI2 or Strep-tactin ISG15 with either MYC-DDK-GDI2wt or the indicated GDI2 mutants. After 48 h, cells were lysed and subjected to a Strep-tactin pulldown. The ISGylation status of the different GDI2 mutants was measured by determining the levels of GDI2 co-precipitated with ISG15. Blots show the results of the pulldown and a 5% of the total lysates (Input). E Analysis of Akt activation in crGDI2 by WB of WT and crGDI2 cells stimulated with EGF 10 ng/ml for 10 min. pAkt is pSer473.
Fig. 6  ISGylation of GDI2 reduces its activity and increases Akt activation. A Representative confocal images, obtained at 60x, of WT and crGDI2 cells pre-treated with cycloheximide for 15 min. and stimulated for 10 min. with EGF 10 ng/ml. EGFR in green, GM130 as Golgi marker in red, phalloidin in grey and DAPI, in blue. At top right of each image, zoom of Golgi structure displayed. At bottom right of each image, visualisation of the co-localisation between EGFR and the Golgi marker GM130 of the images in yellow and DAPI, in blue as reference. 20 µm scale bars are displayed in the bottom-left corner.

B Bar graph shows the average EGFR-GM130 co-localisation showed in A using Costes method, average ± SD; n = 8 field of view.

C WB of WT cells transfected with MYC-DDK-GDI2wt, or MYC-DDK-GDI2-KRtrip and after 48 h were lysed and subjected to Flag IP. GDI2 activity was measured by the levels of Rab5 detected in the pulldowns. Blots show the pulldowns and a 5% of the total lysates (Input).

D Analysis of the effect GDI2-KRtrip has on Akt activation. WB of lysates from WT cells, crGDI2 cells, crGDI2 cells transfected GDI2wt or GDI2-KRtrip, treated for 10 min. with EGF. Values at in the upper part of the WB show the pAkt/Akt ratio as measure of Akt activation, normalised to the ratio in WT cells.

E Quantification of EGFR-GM130 co-localisation displayed in Fig. S7. Bar graph of the average EGFR co-localisation with GM130 using Costes method ± SD of WT cells, crGDI2 cells, crGDI2 transfected with GDI2 expression vector, GDI2wt, or with the mutant GDI2, GDI2-KRtrip, treated for 10 min. with EGF. n = 8 fields of view. p value < 0.05 (*), p value < 0.005 (***)
them unlikely drivers. Having failed to identify a strong candidate, we devised a more targeted, secondary screen.

To map proteins covalently modified by ISG15, the ISGylome, we immunoprecipitated endogenous ISG15, determined which proteins co-immunoprecipitated with ISG15 and used crISG15 as negative control for ISG15 and crUSP8 as negative control for ISGylation. To prevent any non-covalent interactions, we lysed the cells under denaturing conditions prior to the immunoprecipitation step. Analysis of the data revealed 156 proteins as possible ISGylation targets (Table S2). When compared with previous reported ISG15 interactors in the BIOGRID database, 92 were novel targets for ISGylation. Clustering of potential ISGylation targets...
ISG15 correlates positively with Akt activation in breast cancers. A Correlation analysis of ISG15 and UBE2L6 mRNA expression levels in breast cancer samples. The spearman’s correlation is 0.66, p value < 2.2e-16 B Boxplots showing the correlation between an Akt-activity gene-signature and ISG15 mRNA in in lymph node negative basal breast cancer (n = 68), luminal A (n = 174), and luminal B (n = 41), p values are displayed below each graph. C Boxplots showing the correlation between an Akt-activity gene-signature and ISG15 mRNA in in lymph positive basal breast cancer (n = 36), luminal A (n = 188) and luminal B (n = 53), p values are displayed below each graph. D Correlation between pAkt and ISG15 mRNA levels in tumours without lymph node metastasis as a whole (n = 66) or classified by subtype; luminal A (n = 62), luminal B (n = 17), basal (n = 28) and HER2 + (n = 6). E Consistency of correlation as in D in tumours positive for lymph node metastasis as a whole (n = 156) or classified by subtype; Luminal A (n = 65), Luminal B (n = 18), Basal (n = 13) and HER2 + (n = 9). F As B for UBE2L6 mRNA expression. In red boxes, tumour subtypes that showed a statistically significant correlation between pAkt and ISG15 or UBE2L6 mRNA.

using STRING (www.string-db.org) (Table S2) indicated that ISG15 is conjugated to proteins associated with a broad range of cell functions, including endosomal trafficking.

Surprisingly, when comparing the results from both screens, only one protein was in common, phosphoglycerate kinase 1. This suggests that: firstly, the effect ISGylation has on Akt signalling or endosomal trafficking is not related to protein stability, and secondly, that ISGylation does not primarily regulate protein stability under basal conditions.

ISGylation reduces GD2 affinity for Rabs

One of the putative ISGylation substrates identified was GDP Dissociation Inhibitor 2 (GD2) (Fig. 5A). GD2 is a regulator of Rab activity and localisation making it a plausible integrator of ISGylation and endosomal trafficking. Additionally, GD2 was described to be a putative target for ISGylation in two different studies [26, 50]. To confirm that GD2 is ISGylated, we expressed Myc-DDK tagged GD2, Strep-tactin tagged ISG15 or both, and determined the presence or absence of ISGylated GD2. We detected the presence of exogenous GD2 with a shift of the apparent molecular weight only in WT (Fig. 5B) confirming that GD2 is ISGylated under basal conditions.

Neither the protein expression screen (Fig. 5A) nor a WB analysis of GD2 levels (Fig. 5B) showed any changes in GD2 protein levels in the different cell lines. Therefore, we hypothesised that ISGylation of GD2 may be affecting GD2 function rather than stability. To test this, we analysed the ability of GD2 to interact with Rabs in the presence or absence of ISGylation. We transfected Myc-DDK-GD2 into WT, crISG15, crUBC8, crUSP18 and analysed the interactome (Fig. S7C; Table S3). We found several Rabs to be interacting specifically with GD2. Rab5 and Rab11, co-precipitated at higher levels with GD2 in the cells where ISG15 or UBC8 had been knocked-out. In contrast, association of Rabs with GD2 decreased further in crUSP18 cells. Surprisingly, transfected exogenous GD2 was expressed at consistently increased levels in crISG15 cells (Table S3). However, this effect was absent in crUBC8, which indicates that this is not dependent on ISGylation. Rab5 and Rab11 are required for the maturation of early and recycling endosomes respectively [51, 52]. Rab5 is a key regulator of endosomal trafficking, making it a strong candidate to causally link the differences in EGFR recycling to ISGylation. To corroborate these results, we transfected WT and crISG15 cells with Myc-DDK-GD2 and assayed endogenous Rab5 in the immunoprecipitate by WB (Fig. 5C). GD2 co-precipitated higher levels of Rab5 in crISG15 cells when compared to WT, indicating that ISGylation inhibits the complex formation between GD2 and Rab5, which in turn may affect EGFR recycling.

ISG15 modified several lysine-residues of GD2

To identify potential ISGylation sites on GD2 we overexpressed GD2 in COS1 cells and treated the cells with INFb1 to boost ISGylation. Analysis by LC-MS/MS indicated that lysine 435 (Fig. S7D, F) was modified by a double glycine peptide, a residual tag consistent with ISGylation. INFb1 treatment increased the level of the modification, suggesting that this may be an ISGylated residue. In addition, we mined databases for potential ISGylation sites. ISG15 and ubiquitin share the same Lysine–Glycine–Glycine (K-GG) peptide mark when digested with trypsin and are therefore indistinguishable from each other. We interrogated the Phosphosite database (www.phosphosite.org) for K-GG sites detected on GD2 and found that peptides containing lysine 54, 77, 164, 165, 221 and 390 have been identified with the Ubiquitination/ISGylation marker.

To test if any of these sites could be ISGylated we substituted each lysine for arginine, creating the following mutants: K45R/K57R, K164R/K165R, K221R, K390R, K435R as well as combinations of several locations such as K221R/K390R and K221R/K390R/K435R. Analysis by Streptactin-ISG15 pull-downs (Fig. 5D) showed that no single site mutant significantly decreases ISGylation. The double mutant, K164R/K165R, showed a marked decrease in ISGylation, but this was linked to a decrease in protein level, suggesting that the mutations were detrimental to protein expression/stability. A marked reduction in ISG15 conjugation was detected when GD2 was mutated at K221, 390 and 435, suggesting that ISG15 can be conjugated to these sites.

We had observed that GD2 binding to Rabs is enhanced in cells devoid of ISGylation and that absence of ISGylation impaired Akt activation (Fig. 3A, B). To investigate if those two events are causally linked, we knocked-out GD2 in MDA-MB-231-luc-D3H2LN cells (crGD2). Firstly, we treated WT and crGD2 cells with EGFR. crGD2 cells responded with a two-fold increased Akt phosphorylation compared to controls (Figs. 5E, S7E), suggesting that knock-out of GD2 enhances signalling through the PI3K/Akt pathway. We went on to determine how loss of GD2 influenced EGFR trafficking to the Golgi by immunofluorescence (Fig. 6A) and observed a reduction of EGFR co-localising with the Golgi-marker GM130 (Fig. 6B). Secondly, our data suggested that ISGylation of GD2 inhibits the ability of GD2 to interact with Rabs. To test this, we transfected WT cells with either GD2wt or the triple mutant K221R/K390R/K435R (GD2-KRtrip), immunoprecipitated GD2, and assessed the ability to interact with Rab5. We detected a higher binding of Rab5 to GD2-KRtrip (Fig. 6C), confirming that, despite mutating three K residues, the mutant retained the ability of GD2 to bind to Rabs. Moreover, removing these ISGylation sites increased the ability of GD2 to interact with Rab5. Thirdly, to tie these results together, we performed a rescue experiment by transfecting crGD2 cells with either GD2wt or GD2-KRtrip to endogenous levels and analysed the phenotype. Re-expression of GD2wt was able to reduce pAkt to a level similar to the WT cells (Fig. 6D). More interestingly, GD2-KRtrip reduced pAkt levels further still.

To determine if the enhanced activation of Akt caused by GD2 knockdown is associated with reduced EGFR trafficking to the Golgi, we analysed EGFR localisation in WT cells, crGD2 cells and in crGD2 rescued by expressing GD2wt or GD2-KRtrip. We found that knocking out GD2 reduced the presence of EGFR at the Golgi. This reduction was rescued by re-expressing GD2. Intriguingly, rescuing crGD2 with GD2-KRtrip further increased the localisation of EGFR to the Golgi to a level beyond the WT cells (Figs. 5E and S8A, B).

Taken together, these experiments demonstrate that GD2 is ISGylated, ISGylation of GD2 inhibits binding to Rabs, and

Fig. 7 ISG15 correlates positively with Akt activation in breast cancers. A Correlation analysis of ISG15 and UBE2L6 mRNA expression levels in breast cancer samples. The spearman’s correlation is 0.66, p value < 2.2e-16 B Boxplots showing the correlation between an Akt-activity gene-signature and ISG15 mRNA in in lymph node negative basal breast cancer (n = 68), luminal A (n = 174), and luminal B (n = 41), p values are displayed below each graph. C Boxplots showing the correlation between an Akt-activity gene-signature and ISG15 mRNA in in lymph positive basal breast cancer (n = 36), luminal A (n = 188) and luminal B (n = 53), p values are displayed below each graph. D Correlation between pAkt and ISG15 mRNA levels in tumours without lymph node metastasis as a whole (n = 66) or classified by subtype; luminal A (n = 62), luminal B (n = 17), basal (n = 28) and HER2 + (n = 6). E Consistency of correlation as in D in tumours positive for lymph node metastasis as a whole (n = 156) or classified by subtype; Luminal A (n = 65), Luminal B (n = 18), Basal (n = 13) and HER2 + (n = 9). F As B for UBE2L6 mRNA expression. In red boxes, tumour subtypes that showed a statistically significant correlation between pAkt and ISG15 or UBE2L6 mRNA.
inhibiting GDI2 ISGylation suppresses Akt signalling by shunting EGFR towards the Golgi.

**ISG15 expression correlates with Akt-signalling in human tumours**

To determine if ISG15/ISGylation and Akt signalling correlated in human breast tumours, we mined The Cancer Genome Atlas (TCGA) database (http://cancergenome.nih.gov/). TCGA has no protein expression data for ISG15 or UBC8, for this reason we used mRNA levels as surrogates. To establish if we could equate expression of ISG15 with ISGylation, we determined the correlation between ISG15 levels and UBC8 (Fig. 7A). Both genes were highly correlated, showing that high ISG15 could be taken as indicative of high ISGylation. With this assumption, we mined the database for a possible correlation between ISG15 mRNA levels and a PI3K/Akt activation gene signature [53]. The analysis revealed a significant correlation between ISG15 mRNA levels and Akt pathway activity in basal, luminal A and luminal B subtypes regardless of the lymph node status (Fig. 7B, C). In addition, TCGA includes a data set for which pAkt has been measured by RPPA. Here, ISG15 mRNA expression showed no correlation with pAkt in lymph node negative patients and a modest negative one for luminal B (Fig. 7D). However, in basal tumours with lymph node metastasis a positive correlation between ISG15 mRNA and pAkt was found (Fig. 7E) (P value = 0.0012). Interestingly, the same correlation was also found in for UBE2L6 mRNA in Luminal B (P value = 0.0169) and basal tumours (P value = 0.0182) with lymph node metastasis (Fig. 7F). This suggests that in human basal breast cancer UBC8-dependent ISGylation correlates with enhanced pAkt and signalling though the PI3K/Akt pathway.

Taken together, these data support the hypothesis that high levels of ISGylation mediated by UBC8 enhances the malignancy of breast cancer tumours by promoting Akt signalling. Mechanistically, we propose that ISGylation of GDI2 achieves this. ISGylated GDI2 has a lower affinity for Rab proteins, which in turn induces faster receptor recycling to the membrane by reducing the flux of EGFR towards the Golgi. Faster receptor recycling to the membrane then enables the tumour cells to sustain PI3K/Akt activation.

**DISCUSSION**

Metastasis is a main determinant of cancer mortality in solid tumours and an understanding of how the primary tumour acquires the ability to form secondary cancers is key to target the process. Altered EGFR-family RTK signalling is commonly associated with the induction of aggressive tumour characteristics, such as invasion, proliferation, or angiogenesis in breast tumours [54, 55]. To complement the picture, our data show that ISG15, UBE2L6 expression and prognosis are inversely associated with the induction of aggressive tumour characteristics, such as invasion, proliferation, or angiogenesis in breast tumours [56]. ISGylation levels directly correlate with high recycling rates and decreased flux towards the Golgi apparatus. This effect is due to ISGylation of GDI2, a regulator of Rab localisation and activity [60]. GDI2 contains two conserved domains, a protein-protein interaction domain, the Rab-binding platform, and a protein-lipid interaction domain, or lipid binding pocket, connected by the GDI effector loop [61]. We found that GDI2 ISGylation is not restricted to one residue. Of the three sites identified as ISGylated, lysine 221 may be the most relevant for the Rab interaction. Sequence alignments suggest that it is at the junction between the hinge and the lipid-binding domain, towards the side of the protein that interacts with Rab. It is plausible that ISGylation of Lysine 221 could limit the interaction with the C-terminal prenyl group of the interacting Rab, the key step for the GDI-mediated extraction of Rab-GTPases from the membrane [62]. Further research is needed to establish how ISGylation of these residues regulates GDI2 activity. It is tempting to hypothesise that receptor trafficking is dependent on the balance between Rab and GDI2, thus, in different cell types with different expression levels, ISGylation of GDI2 may affect RTKs mediated signalling distinctly. Furthermore, the analysis of the GDI2 interactorome showed that the interaction of additional Rabs, was regulated by ISGylation. Consequently, absence of ISG15 could trigger other, unexplored defects, such as trafficking of de novo synthesised proteins from either the ER or Golgi, but further work is needed to test this.

**MATERIALS AND METHODS**

Cell lines: MDA-MB-231 subclone D3H2LN, Cos1 and HEK293t were grown in DMEM 4.5 g/l glucose supplemented with 10% foetal bovine serum and 2 mM glutamine, at 37 °C and 5% CO2.

Proteomics: Changes in whole proteome levels were analysed using the Filter Aided Sample Preparation method, as previously described [63]. Interaction/ISGylation proteomics samples were analysed as described [64]. EGFR recycling: Recycling assays were performed as described previously [48].

**REFERENCES**

1. Villarroya-Beltri C, Guerra S, Sanchez-Madrid F. ISGylation - a key to lock the cell gates for preventing the spread of threats. J Cell Sci. 2017;130:2961–9.
2. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer. 2006;94:1465–71.
3. Kissingler A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L, et al. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009;28:2606–20.
4. Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, et al. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorgenesis and metastasis of hepatocellular carcinoma. Oncotarget. 2014;5:8429–41.
5. Padovano E, Terracciano L, Certa U, Jacobs B, Reschner A, Bolli M, et al. Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res. 2002;62:3453–8.
6. Talviken K, Tuikala J, Gronroos J, Huhtinen H, Kronqvist P, Aittokallio T, et al. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res. 2006;26:4745–51.
7. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008;10:R58.
8. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA. 2008;105:18490–5.
9. Nabet BY, Qi Y, Shabason JE, Wu TJ, Yoon T, Kim BC, et al. Exosome RNA unshields couples stromal activation to pattern recognition receptor signaling in cancer. Cell. 2017;170:352–66 e313.
10. Loeb KR, Haas AL. The interferon-inducible 15-Kda ubiquitin homolog conjugates to intracellular proteins. J Biol Chem. 1992;267:7806–13.
11. Malakoff MP, Malakova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem. 2002;277:9976–81.
12. Korant BD, Blomstrom DC, Jonak GJ, Knight E. Interferon-induced proteins—purification and characterization of a 15,000-Dalton protein from human and bovine cells induced by interferon. J Biol Chem. 1984;259:4835–9.
13. Malakova O, Malakov M, Hetherington C, Zhang DE. Lipopolysaccharide acti-
vates the expression of ISG15-specific protease UBPF3 via interferon regulatory
factor 3. J Biol Chem. 2002;277:14703–11.
14. Farrell J, Kelly C, Rauch J, Kida K, Garcia-Munoz A, Monsel N, et al. HGF induces
epithelial-to-mesenchymal transition by modulating the mammalian hippo/MST2
and ISG15 pathways. J Proteome Res. 2014;13:2874–86.
15. Haas AL, Ahmedov B, Bright PM, Ahn K. Interferon induces a 15-kilodalton protein
expressing marked homology to ubiquitin. J Biol Chem. 1987;262:13135–23.
16. Boelens MC, Wu TJ, Nabet BY, Xu B, Qi Y, Yoon T, et al. Exosome transfer from
stromal to breast cancer cells regulates therapy resistance pathways. Cell.
2014;159:499–513.
17. Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS
surveillance of micrornuclei links genome instability to innate immunity. Nature.
2017;548:461–5.
18. Knight E Jr., Cordova B. IFN-induced 15-kDa protein is released from human
lymphocytes and monocytes. J Immunol. 1991;146:2280–4.
19. Villarreal DO, Wise MC, Siefert RJ, Yan J, Wood LM, Weiner DB. Ubiquitin-like
molecule ISG15 acts as an immune adjuvant to enhance antigen-specific CD8
cell-tumor immunity. Mol Ther. 2015;23:1653–62.
20. D’Cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E Jr., Borden EC. In vitro and
in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine.
J Immunol. 1996;157:4100–8.
21. Burks J, Reed RE, Desai SD. Free ISG15 triggers an antitumor immune response
to breast cancer: a new perspective. Oncotarget. 2015;6:2271–31.
22. Sainz B Jr., Martin B, Tatari M, Heeschen C, Guerra S. ISG15 is a critical micro-
RNA target for breast cancer. Oncogene. 2014;33:794–9.
23. Morales DJ, Lenschow DJ. The antiviral activities of ISG15. J Mol Biol.
2008;382:410–24.
24. Hermann M, Bogunovic D. ISG15: in sickness and in health. Trends Immunol.
2013;34:368–80.
25. Giannakopoulos NV, Luo JX, Kapov P, Vouz W, Lenschow DJ, Jacobs BS, et al.
Proteomic identification of proteins conjugated to ISG15 in mouse and human
cells. Biochem Biophys Res Commun. 2005;336:496–506.
26. Zhao C, Denison C, Huijbertse JM, Gyi S, Krug RM. Human ISG15 conjugation
targets both IFN-induced and constitutively expressed proteins functioning in
diverse cellular pathways. Proc Natl Acad Sci USA. 2005;102:10200–5.
27. Malakova OP, Kim KJ, Malakova OA, Jacobs BS, Borden EC, Zhang DE. High-
throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key reg-
gulators of signal transduction. J Biol Chem. 2003;278:16608–13.
28. Desai SD, Haas AL, Wood LM, Tsai YC, Pestika S, Rubin EH, et al. Elevated
expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome
pathway. Cancer Res. 2006;66:921–8.
29. Yuan W, Krug RM. ISGylation modulates the JAK-STAT signaling pathway. Genes
Dev. 2001;20:362–73.
30. Huang YF, Wee SL, Gunaratne J, Lane DP, Bulavin DV. Isg15 controls p53 stability
and targets both IFN-induced and constitutively expressed proteins functioning in
diverse cellular pathways. Proc Natl Acad Sci USA. 2005;102:444–58.
31. Cerikan B, Shaheen R, Colo GP, Glasser C, Hata S, Knobeloch KP, et al. Cell-intrinsic
ISGylation links immune adjuvant to enhance antigen-specific CD8+ cell-tumor
immunity. Mol Ther. 2019;27:655–60.
32. Takeuchi T, Iwahara S, Saeki Y, Sasajima H, Yokosawa H. Link between the ubi-
quitin conjugation system and the ISG15 conjugation system: ISG15 conjugation
to the UbC6 ubiquitin E2 enzyme. J Biochem. 2005;138:711–20.
33. Reich N, Evanson L, Levy D, Fahey D, Knight E Jr., Darnell JE Jr. Interferon-
induced transcription of a gene encoding a 15-kDa protein depends on an upstream
enhancer element. Proc Natl Acad Sci USA. 1987;84:6394–8.
34. Malakova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, et al. UBPF3 is a novel
regulator of interferon signaling independent of its ISG15 isopeptidase activity.
EMBO J. 2006;25:2358–67.
35. Shin J, Kim G, Lee JW, Lee JE, Kim YS, Yu JH, et al. Identification of ganglioside
GM2 activator playing a role in cancer cell migration through proteomic analysis
of breast cancer secretomes. Cancer Sci. 2016;107:828–35.
36. Ankney JA, Xie L, Wrobel JA, Wang L, Chen X. Novel secretome-to-transcriptome
integrated or sero-only transcriptomic approach to reveal liquid biopsy biomarkers
for predicting individualized prognosis of breast cancer patients. BMC Med
Genet. 2015;6:20.
37. Yanez E, Garcia-Culebras A, Frau A, Llompart C, Knobeloch KP, Gutierrez-
Erlandsson S, et al. ISG15 regulates peritoneal macrophages functionality against
viral infection. PLoS Pathog. 2013;9:e1003632.
38. Malakova OA, Yan M, Malakov MP, Yuan Y, Ritchie KJ, Kim KI, et al. Protein ISGylation
modulates the JAK–STAT signaling pathway. Genes Dev. 2014;28:1675–89.
39. Sooyanarrain H, Rogers AJ, Cao D, Haac MER, Grinstein S. Cholesterol uptake
mediated by LRP1 in human macrophages in response to Chlamydia trachomatis.
J Biol Chem. 2000;275:5297–305.
40. Turriziani B, Garcia-Munoz A, Pilkington R, Raso C, Kolch W, von Kriegsheim A. On-
beads digestion in conjunction with data-dependent mass spectrometry: a shortcut
to quantitative and dynamic interaction proteomics. Biology. 2014;3:320–32.
ACKNOWLEDGEMENTS
We thank Ana Herrero for help with the cellular fractionation method, Breast Cancer NOW (2013NovPR183), Cancer Research UK. Cancer Research UK (CRUK Edinburgh Centre C157/A255140 & C157/A24837), Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z & Centre for Cell-Matrix Research 203128/A/16/Z), MRC (core funding to the MRC Human Genetics Unit MRC grant MC_UU_00007/16 & MR/R009376/1), Worldwide Cancer Research (14–1226), Australia’s Victorian Cancer Agency (MCRF18026), BREAST-PREDICT (CCRC13GAL) and Science Foundation Ireland (15/ IA/3104) for funding.

AUTHOR CONTRIBUTIONS
ABC, PC: data acquisition, analysis, interpretation and manuscript writing; ML, MW, KMcL: data acquisition; AE: data interpretation and analysis; WG, LN, VB, NC, CS: supervision and data interpretation; AvK: supervision, data interpretation and manuscript writing.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41388-021-02017-8.

Correspondence and requests for materials should be addressed to Alex von Kriegsheim.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021